MA33563B1 - 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl - Google Patents

5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Info

Publication number
MA33563B1
MA33563B1 MA34662A MA34662A MA33563B1 MA 33563 B1 MA33563 B1 MA 33563B1 MA 34662 A MA34662 A MA 34662A MA 34662 A MA34662 A MA 34662A MA 33563 B1 MA33563 B1 MA 33563B1
Authority
MA
Morocco
Prior art keywords
hdl cholesterol
trichloroetoxy
nectanamide
dichlorophenyl
cyclohexyl
Prior art date
Application number
MA34662A
Other languages
Arabic (ar)
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33563B1 publication Critical patent/MA33563B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Cette invention concerne un composé représenté par tous les isomères de la formule et ses sels pharmaceutiquement acceptables, leur fabrication, les compositions pharmaceutiques les contenant et leur utilisation en tant que médicaments dans le traitement et/ou la prophylaxie des maladies pouvant être traitées par des agents augmentant le cholestérol hdl, notamment la dyslipémie, l'athérosclérose et les maladies cardiovasculaires.
MA34662A 2009-09-11 2012-03-05 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl MA33563B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (fr) 2009-09-11 2010-09-08 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Publications (1)

Publication Number Publication Date
MA33563B1 true MA33563B1 (fr) 2012-09-01

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34662A MA33563B1 (fr) 2009-09-11 2012-03-05 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Country Status (35)

Country Link
US (1) US8227491B2 (fr)
EP (1) EP2475645B1 (fr)
JP (1) JP5604520B2 (fr)
KR (1) KR101382871B1 (fr)
CN (1) CN102639506B (fr)
AR (2) AR078352A1 (fr)
AU (1) AU2010294277B2 (fr)
BR (1) BR112012005511B8 (fr)
CA (1) CA2771493C (fr)
CL (1) CL2012000611A1 (fr)
CO (1) CO6491033A2 (fr)
CR (1) CR20120089A (fr)
CY (1) CY1114377T1 (fr)
DK (1) DK2475645T3 (fr)
EC (1) ECSP12011723A (fr)
ES (1) ES2423821T3 (fr)
HK (1) HK1172021A1 (fr)
HR (1) HRP20130869T1 (fr)
IL (1) IL217920A (fr)
IN (1) IN2012DN00763A (fr)
MA (1) MA33563B1 (fr)
MX (1) MX2012002254A (fr)
MY (1) MY161103A (fr)
NZ (1) NZ597514A (fr)
PE (1) PE20120863A1 (fr)
PL (1) PL2475645T3 (fr)
PT (1) PT2475645E (fr)
RS (1) RS52987B (fr)
RU (1) RU2541475C2 (fr)
SG (1) SG179035A1 (fr)
SI (1) SI2475645T1 (fr)
TW (1) TWI412363B (fr)
UA (1) UA107088C2 (fr)
WO (1) WO2011029827A1 (fr)
ZA (1) ZA201201599B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (fr) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Détermination des niveaux de protéine abca1 dans des cellules
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (fr) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Procédés d'identification de modulateurs d'osbpl7 et utilisation de ces modulateurs pour traiter les maladies associées à osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
DK1868999T3 (da) * 2005-04-06 2009-08-17 Hoffmann La Roche Pyridin-3-carboxamidderivater som omvendte CB1-agonister
BRPI0717845A2 (pt) 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos

Also Published As

Publication number Publication date
US20110065759A1 (en) 2011-03-17
BR112012005511A2 (pt) 2016-04-19
KR20120048040A (ko) 2012-05-14
MX2012002254A (es) 2012-03-16
HK1172021A1 (en) 2013-04-12
CY1114377T1 (el) 2016-08-31
CA2771493A1 (fr) 2011-03-17
NZ597514A (en) 2013-10-25
CO6491033A2 (es) 2012-07-31
CL2012000611A1 (es) 2012-09-07
AR114032A2 (es) 2020-07-15
UA107088C2 (xx) 2014-11-25
PT2475645E (pt) 2013-08-05
HRP20130869T1 (hr) 2013-10-25
AU2010294277B2 (en) 2015-07-09
US8227491B2 (en) 2012-07-24
CN102639506A (zh) 2012-08-15
ZA201201599B (en) 2012-11-28
RU2012113924A (ru) 2013-10-20
DK2475645T3 (da) 2013-07-22
WO2011029827A1 (fr) 2011-03-17
CN102639506B (zh) 2014-09-03
AU2010294277A1 (en) 2012-02-09
RS52987B (en) 2014-02-28
AR078352A1 (es) 2011-11-02
SI2475645T1 (sl) 2013-10-30
RU2541475C2 (ru) 2015-02-20
IL217920A (en) 2015-11-30
ECSP12011723A (es) 2012-04-30
EP2475645B1 (fr) 2013-07-03
IL217920A0 (en) 2012-03-29
JP2013504534A (ja) 2013-02-07
KR101382871B1 (ko) 2014-04-08
BR112012005511B1 (pt) 2021-03-02
TWI412363B (zh) 2013-10-21
TW201114427A (en) 2011-05-01
ES2423821T3 (es) 2013-09-24
BR112012005511B8 (pt) 2021-05-25
MY161103A (en) 2017-04-14
IN2012DN00763A (fr) 2015-06-26
JP5604520B2 (ja) 2014-10-08
PL2475645T3 (pl) 2013-12-31
EP2475645A1 (fr) 2012-07-18
CR20120089A (es) 2012-03-22
PE20120863A1 (es) 2012-07-23
SG179035A1 (en) 2012-04-27
CA2771493C (fr) 2017-08-29

Similar Documents

Publication Publication Date Title
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA38138A1 (fr) Dérivés inédits de quinolone
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35285B1 (fr) Indazoles
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA32563B1 (fr) Dabigatran pour cathétérisme cardiaque de chirurgie percutanée
MA38556A1 (fr) Inhibiteurs de bace1
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine